WMSA
LYEL icon

Weiss Multi-Strategy Advisers’s Lyell Immunopharma LYEL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-735
Closed -$218K – 728
2021
Q3 		$218K Sell
735
-515
-41% -$154K ﹤0.01% 622
2021
Q2 		$406K Buy
+1,250
New +$410K 0.01% 571

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Weiss Multi-Strategy Advisers's LYEL Position: Q4 2021 in Review

Weiss Multi-Strategy Advisers sold out of Lyell Immunopharma (LYEL) in Q4 2021, closing a stake of 735 shares — an estimated $218K sold.

Weiss Multi-Strategy Advisers first reported a position in LYEL in Q2 2021 and held it in 2 quarters. The position peaked at $406K in Q2 2021. 77 funds tracked by Wall St. Rank hold LYEL as of Q4 2021.

  • Weiss Multi-Strategy Advisers reported no remaining Lyell Immunopharma position as of Q4 2021 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 735 Lyell Immunopharma shares in Q4 2021, an estimated $218K.
  • Weiss Multi-Strategy Advisers first reported a position in Lyell Immunopharma in Q2 2021 and held it in 2 quarters.
  • Weiss Multi-Strategy Advisers's Lyell Immunopharma position peaked at $406K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.